Instead of replacing clinical trials, real-world data will be used to supplement traditional clinical trial information, said Viraj Narayanan, MBA, vice president of Life Sciences at COTA Healthcare.
Instead of replacing clinical trials, real-world data will be used to supplement traditional clinical trial information, said Viraj Narayanan, MBA, vice president of Life Sciences at COTA Healthcare.
Transcript:
How should real-world data be used in conjunction or alongside clinical trial methods?
I think one of the most common myths or misconceptions we hear is that real-world data is going to replace clinical trials. I certainly do not hold that perspective. I think it's going to be augmenting and supplementing traditional clinical trial information. When you think about how it can augment clinical trial information, probably the use case that we're most excited about is for single arm clinical trials, where the sponsor is essentially using their investigational agent for a subset of patients and a treatment arm. You're trying to match that treatment arm to like patients in the real world. If this use case can really take off, we're talking about rewiring the traditional clinical trial process: taking millions of dollars out of the system, getting patients to drugs who really need them earlier.
Impact of Amivantamab-Lazertinib on EGFR, MET Resistance Alterations in NSCLC: Danny Nguyen, MD
September 15th 2025The combination of amivantamab and lazertinib in first-line non–small cell lung cancer (NSCLC) significantly reduces resistance mechanisms with implications for second-line treatment, said Danny Nguyen, MD, of City of Hope.
Read More
Disparities in Biomarker Testing Impact Nonsquamous NSCLC Outcomes: Surbhi Singhal, MD
September 6th 2025Surbhi Singhal, MD, of the University of California Davis, discussed disparities in biomarker testing among patients diagnosed with stage IV nonsquamous non–small cell lung cancer (NSCLC).
Read More